Abstract
Herpes Simplex Virus (HSV) has a number of advantages as a gene delivery vector, particularly for the nervous system. Thus, it naturally establishes asymptomatic latent infections of neuronal cells. Moreover, it is readily grown in culture to high titre and has a large genome so allowing it to be used to deliver multiple or very large genes. Considerable progress has been made in effectively disabling the virus so that it does not damage the cells it infects but can still deliver an inserted gene effectively. In addition, it is now possible to obtain long-term expression of the transgene in the nervous system, using regulatory elements derived from the latency-associated transcript of the virus. As well as its use in the nervous system, the virus has also been used to successfully deliver genes to a variety of other cell types, including peripheral blood mononuclear cells and cardiac myocytes within the intact heart. In particular, its ability to deliver genes effectively to replicating cancer cells and to dendritic cells offers considerable potential for the use of this virus in cancer therapy.
Current Gene Therapy
Title: Herpes Simplex Virus Vectors for Gene Delivery to a Variety of Different Cell Types
Volume: 2 Issue: 4
Author(s): David S. Latchman
Affiliation:
Abstract: Herpes Simplex Virus (HSV) has a number of advantages as a gene delivery vector, particularly for the nervous system. Thus, it naturally establishes asymptomatic latent infections of neuronal cells. Moreover, it is readily grown in culture to high titre and has a large genome so allowing it to be used to deliver multiple or very large genes. Considerable progress has been made in effectively disabling the virus so that it does not damage the cells it infects but can still deliver an inserted gene effectively. In addition, it is now possible to obtain long-term expression of the transgene in the nervous system, using regulatory elements derived from the latency-associated transcript of the virus. As well as its use in the nervous system, the virus has also been used to successfully deliver genes to a variety of other cell types, including peripheral blood mononuclear cells and cardiac myocytes within the intact heart. In particular, its ability to deliver genes effectively to replicating cancer cells and to dendritic cells offers considerable potential for the use of this virus in cancer therapy.
Export Options
About this article
Cite this article as:
Latchman S. David, Herpes Simplex Virus Vectors for Gene Delivery to a Variety of Different Cell Types, Current Gene Therapy 2002; 2 (4) . https://dx.doi.org/10.2174/1566523023347698
DOI https://dx.doi.org/10.2174/1566523023347698 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Fgf10: A Paracrine-Signaling Molecule in Development, Disease, and Regenerative Medicine
Current Molecular Medicine VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Endogenous Angiogenesis Inhibitors as Therapeutic Agents: Historical Perspective and Future Direction
Recent Patents on Anti-Cancer Drug Discovery From Peptides to Small Molecules: An Intriguing but Intricated Way to New Drugs
Current Medicinal Chemistry Anti-Cancer Approach with NK4: Bivalent Action and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Glycoconjugates: Roles in Neural Diseases Caused by Exogenous Pathogens
CNS & Neurological Disorders - Drug Targets Synthesis of (R)-2-benzylmorpholine employing catalytic stereospecific rearrangement of L-Phenylalaninol
Letters in Organic Chemistry Ganglioside GD3 as a Raft Component in Cell Death Regulation
Anti-Cancer Agents in Medicinal Chemistry Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme
Current Molecular Pharmacology Meet Our Editorial Board Member
Protein & Peptide Letters The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry Amyotrophic Lateral Sclerosis: From Research to Therapeutic Attempts and Therapeutic Perspectives
Current Medicinal Chemistry RAGE as a Receptor of HMGB1 (Amphoterin): Roles in Health and Disease
Current Molecular Medicine Therapeutic Strategies to Target Multiple Kinases in Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression
Current Topics in Medicinal Chemistry The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery Uncertainty in the Translation of Preclinical Experiments to Clinical Trials. Why do Most Phase III Clinical Trials Fail?
Current Gene Therapy COX-2, Cell Proliferation and PMA in Head-and-Neck Cancer Cells
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nanoparticle-mediated Drug Delivery Systems (DDS) in the Central Nervous System
Current Organic Chemistry